GlassScriptPhysician profile
Viswanathan Iyer
NPI 1871718338
$4,809.11
in general payments reported to CMS, 2019-2025
24 companies · $1,445 in 2025
The $1,445 reported for 2025 was more than what 85% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $438 · 2020: $36.38 · 2021: $295 · 2022: $499 · 2023: $735 · 2024: $1,361 · 2025: $1,445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,516 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,516.41 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $526.53 | 2019-2025 | Veltassa, Korsuva |
| Astrazeneca Pharmaceuticals LP | $524.82 | 2019-2025 | Lokelma, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $517.96 | 2021-2025 | |
| Ardelyx, INC. | $383.71 | 2023-2025 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $362.75 | 2024-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $277.52 | 2019-2025 | Jynarque, Voyxact |
| Fresenius USA Marketing, INC. | $264.66 | 2019-2025 | Velphoro, Velphoro |
| Akebia Therapeutics INC | $259.86 | 2019-2025 | Vafseo |
| Amgen INC. | $244.90 | 2019-2025 | Tavneos, Krystexxa |
| Calliditas Therapeutics US INC. | $223.80 | 2023-2025 | Tarpeyo |
| Mallinckrodt Hospital Products INC. | $206.15 | 2022-2024 | Acthar, Terlivaz |
| Travere Therapeutics, INC. | $198.41 | 2023-2025 | |
| Opko Pharmaceuticals, LLC | $159.68 | 2020-2025 | Rayaldee |
| Ani Pharmaceuticals, INC. | $142.07 | 2024-2025 | Purified Cortrophin Gel |
| Novartis Pharmaceuticals Corporation | $120.40 | 2023-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $82.25 | 2022-2024 | Benlysta, Jesduvroq |
| Takeda Pharmaceuticals U.S.A., INC. | $75.41 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $64.10 | 2019-2022 | |
| Kyowa Kirin, INC. | $47.66 | 2023-2024 | Crysvita |
| Scpharmaceuticals INC. | $41.92 | 2025 | |
| Aurinia Pharma U.S., INC. | $32.30 | 2021-2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $24.38 | 2024 | |
| Daiichi Sankyo INC. | $15.42 | 2022 | |
| Janssen Pharmaceuticals, INC | $12.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Viswanathan Iyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.